TUMOR DO ESTROMA GASTROINTESTINAL (GIST) GIGANTE ASSINTOMÁTICO: REVISÃO DE TEMA A PROPÓSITO DE UM CASO CLÍNICO

  • Sofia Valente Interna de Cirurgia Geral; Departamento de Cirurgia; Centro Hospitalar Lisboa Norte, EPE – Hospital de Santa Maria, Portugal http://orcid.org/0000-0002-7917-565X
  • Carlos Miranda Assistente Graduado de Cirurgia Geral – Unidade de Cirurgia Hepato-bilio-pancreática; Departamento de Cirurgia; Centro Hospitalar Lisboa Norte, EPE – Hospital de Santa Maria, Portugal http://orcid.org/0000-0001-9627-8573
  • João Coutinho Assistente Graduado Sénior de Cirurgia Geral – Diretor do Departamento de Cirurgia do Hospital de Santa Maria; Centro Hospitalar Lisboa Norte, EPE, Portugal http://orcid.org/0000-0002-4888-3944

Resumo

Os GIST são tumores mesenquimatosos raros que podem apresentar-se como lesões milimétricas ou massas volumosas. Habitualmente são clinicamente silenciosos até atingirem um tamanho significativo, pelo que a sua identificação é muitas vezes incidental. Apresentamos o caso de uma doente de 92 anos admitida no Serviço de Urgência por dor no hipocôndrio direito (HD), náuseas e vómitos, com horas de evolução. O exame objetivo revelou dor à palpação no HD e uma massa palpável no quadrante superior esquerdo, indolor, de 10 x 10 cm. As análises e ecografia abdominal confirmaram a hipótese diagnóstica de coledocolitíase e revelaram uma massa sólida, heterogénea, com áreas quísticas, de 14 x 8 x 9 cm, com planos de clivagem. Realizada colangiopancreatografia retrógrada endoscópica (CPRE) com esfinterotomia transendoscópica (ETE) e coledocolitotomia, sem intercorrências. A doente foi operada no decurso do internamento, tendo realizado, por laparotomia mediana supraumbilical, resseção de tumor gástrico, com gastrectomia em cunha e colecistectomia. A análise histológica e imuno-histoquímica da lesão mostrou um GIST de alto risco de malignidade. Pela idade avançada da doente e pelas comorbilidades existentes, optou-se por não realizar terapêutica adjuvante com imatinib, como normalmente indicado. A revisão da literatura mostrou que os GIST gigantes do estômago são raros, sendo habitualmente sintomáticos, contrariamente à nossa doente. A ressecção cirúrgica completa é o tratamento de escolha nos GIST localmente ressecáveis, estando a terapêutica adjuvante indicada nos tumores de alto risco.

Downloads

Dados de Download não estão ainda disponíveis.

Referências

1 B. Nilson et al, “Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden,” Cancer, vol. 103(4), pp. 821-829, Feb 2005.

2 K. Søreide et al, “Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies.,” Cancer Epidemiol, vol. 40, pp. 39-46, Feb 2016.

3 A. Koyuncer, L. Gönlusen e A. V. Kutsal, “A rare case of giant gastrointestinal stromal tumor of the stomach involving the serosal surface,” Int J Surgery Case Rep, vol. 12, pp. 90-94, May 2015.

4 Y. Wang, J. Peng e H. Jinbai, “Giant and high-risk gastrointestinal stromal tumor in the abdomino-pelvic cavity: A case report,” Oncology Letters, vol. 11, pp. 2035-2038, 2016.

5 L. Zhou et al, “A rare giant gastrointestinal stromal tumor of the stomach traversing the upper abdomen: a case report and literature review,” Worl Journal of Surgical Oncology, vol. 10, p. 66, 2012.

6 A. Cappellani et al, “Giant gastrointestinal stromal tumor (GIST) of the stomach cause of high bowel obstruction: surgical management,” World Journal Of Surgical Oncology, vol. 11, p. 172, 2013.

7 M. Miettinen e J. Lasota, “Gastrointestinal Stromal Tumors,” Gastroenterol Clin North Am, vol. 42 (2), pp. 399-415, June 2013.

8 S. Hirota et al, “Gain-of-function of c-kit in human gastrointestinal stromal tumors,” Science, vol. 258, pp. 577-580, 1998.

9 L. Kindblom et al, “Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal stromal tumors show phenotypic caractheristics of the interstitial cells of Cajal,” American Journal of Pathology, vol. 153, pp. 1259-1269, 1998.

10 S. Hirota e k. Isozaki, “Pathology of gastrointestinal stromal tumors.,” Pathology International, vol. 56(1), pp. 1-9, Jan 2006.

11 C. Serrano e S. George, “Recent advances in the treatment of gastrointestinal stromal tumors,” Therapeutic Advances in Medical
Oncology, vol. 6 (3), pp. 115-127, 2014.

12 ESMO/European Sarcoma Network Working Group, “Gastrointestinal stromal tumours: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 25(3), pp. iii21-iii26, 2014.

13 J. Lopes, M. Soares et al, “Recomendações para Análise Mutacional em Tumores do Estroma Gastrointestinal (GISTs). Grupo de
Trabalho Português GIST– Proposta de Condeixa,” Revista Portuguesa Cirurgia , vol. 23, pp. 61-68, 2012.

14 J. Lasota e M. Mietten, “Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.,”
Histopathology, vol. 53(3), pp. 245-266, Sep 2008.

15 S. Patil et al, “Giant Gastrointestinal Stromal Tumor Presenting as a Palpable Abdominal Mass: An Unusual Presentation,”
International Scholary Research Network, Mar 2011.

16 D. M. King, “The radiology of gastrointestinal stromal tumours (GIST),” Cancer Imaging, vol. 5, pp. 150-156, 2005.

17 F. Almeida et al, “Ecoendoscopia nas lesões subepiteliais do trato digestório – artigo de revisão,” Revista do Colégio Brasileiro de
Cirurgiões, vol. 39(5), pp. 408-413, 2012.

18 Y.-M. Lin et al, “Unusual gastric tumors and tumor-like lesions: Radiological with pathological correlation and literature review,”
World Journal of Gastroenterology, vol. 23(14), pp. 2493-2504, April 2017.

19 A. Rader et al, “Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit,” Cancer, vol. 93(4), pp. 269-275., 2001.

20 J. DeWitt, R. Emerson et al, “Endoscopic ultrasound-guided trucut biopsy of gastrointestinal mesenchymal tumor,” Surgical
Endoscopic, vol. 25, pp. 192-202, 2011.

21 W. Swalchick, R. Shamekh e M. Bui, ““IS s DOG1 Immunoreactivity Specific to Gastrointestinal Stromal Tumor?”,” Cancer Control,
vol. 22(4), pp. 498-504., Oct; 2015 .

22 L. Lopes et al, ““DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): Comparison between 2 different antibodies”,”
Appl Immunohistochem Mol Morphol, vol. 18(4):, pp. 333-7., Jul 2010.

23 U. Chaudhry e R. DeMatteo, “Advances in the surgical management of gastrointestinal stromal tumor,” Advances in Surgery,
vol. 45, pp. 197-209, 2011.

24 S.-H. Kong e H.-K. Yang, “Surgical Treatment of Gastric Gastrointestinal Stromal Tumor,” J Gastric Cancer, vol. 13 (1), pp. 3-18, 2013.

25 R. DeMatteo et al, “Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival,”
Annals of Surgery, vol. 231, pp. 51-58, 2000.

26 M. McCarter, C. Antonescu et al l, “Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of
Risk Factors and Tumor Recurrence,” Journal of the American College of Surgeons, vol. 215, p. 53–59, Jul 2012.

27 J. Nishimura, K. Nakajima et al, “Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection,”
Surgical Endoscopy, vol. 21(6), p. 875–878, 2007.

28 G. Karakousis et al “Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison,” Annals of Surgical Oncology, vol. 18(6), p. 1599–1605, 2011.

29 M. Ortenzi, R. Ghiselli, L. Cardinali e M. Guerrieri, “Surgical treatment of gastric stromal tumors: laparoscopic versus open
approach,” Ann Ital Chir, vol. 88, 2017.

30 R. DeMatteo, et al e ACOSOG Intergroup Adjuvant GIST Study Team, “Adjuvant imatinib mesylate after resection of localised,
primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial,” Lancet, vol. 373(9669), pp. 1097-
1104, 2009.

31 H. Joensuu, M. Eriksson et al, “One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized
trial,” JAMA, vol. 307(12), pp. 1265-1272, 2012.

32 P. Hohenberger, U. Ronellenfitsch et al, “Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour,” British Journal of Surgery, vol. 97(12), pp. 1854-1859, 2010.

33 M. McCarter, et al e ACOSOG Intergroup Adjuvant GIST Study Team, “Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.,” Journal of the American College of Surgeons, vol. 215(1), pp. 53-59, 2012.

34 F. Haller, S. Detken et al, “Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs)
with respect to imatinib resistance caused by secondary KIT mutations,” Annals of Surgical Oncology, vol. 14(2), pp. 526-532, 2007.

35 A. Le Cesne et al, “Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial,” Lancet Oncol, vol. 11(10), pp. 942-949, 2010.

36 C. Mussi et al, “Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?,” Annals of Oncology, vol. 21(2), pp. 403-8, 2010.

37 C. Raut et al, “Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy
using kinase inhibitors,” Journal of Clinical Oncology, vol. 24(15), pp. 2325-2331, 2006.

38 H. Choi, “Response Evaluation of Gastrointestinal Stromal Tumors,” Oncologist, vol. 13(2), pp. 4-7, 2008.

39 H. Joensuu et al, “Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery,” European Journal of Cancer, vol. 51, pp. 1611-1617, 2015.

40 Y. Kang YK, M. Ryu et al, “Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after
failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial,” Lancet Oncology, vol. 14(12), pp. 1175--1182, 2013.

41 M. Miettinen e J. Lasota, “Gastrointestinal stromal tumors: pathology and prognosis at different sites,” Seminars in Diagnostic
Pathology, vol. 23(2), pp. 70-83, 2006.

42 H. Joensuu, A. Vehtari et al, “Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled populationbased cohort,” Lancet Oncology, vol. 13(3), pp. 265-274, 2012.
Publicado
2021-08-09
Como Citar
VALENTE, Sofia; MIRANDA, Carlos; COUTINHO, João. TUMOR DO ESTROMA GASTROINTESTINAL (GIST) GIGANTE ASSINTOMÁTICO: REVISÃO DE TEMA A PROPÓSITO DE UM CASO CLÍNICO. Revista Portuguesa de Cirurgia, [S.l.], n. 50, p. 57-68, aug. 2021. ISSN 2183-1165. Disponível em: <https://revista.spcir.com/index.php/spcir/article/view/686>. Acesso em: 23 sep. 2021. doi: https://doi.org/10.34635/rpc.686.
Secção
Caso Clínico